Shop

According to the WHO report (2008), human papillomavirus (HPV) causes virtually 100% of cases of cervical cancers. There are more than 100 genotypes of HPV reported currently, and HPV consists of double helix circular DNA with ca. 7,900 bps. Compared to the traditional Pap smear test, HPV genotyping has several advantages; 1) high accuracy of determining existence of HPV viruses, 2) genotyping of the HPV viruses, 3) early diagnosis, 4) identifying patients harboring HPV with high risk type, and 5) contribution to prevention and therapy of cervical cancers in the end.
PANA RealTyper™ HPV kit is an in vitro diagnostic reagent for genotyping of human papilloma virus (HPV) using peptide nucleic acid (PNA) probes. This kit is an amplified DNA test for the qualitative detection of a total of 40 HPV genotypes in a real-time PCR (polymerase chain reaction) system. This kit provides genotyping information of 20 high-risk and 2 low-risk types using melting temperature (Tm) analysis. Furthermore, this kit also detects 18 other genotypes (without genotyping) in DNA samples from clinical specimens

PANAMutyper™ EML4-ALK Screening Kit is the qualitative diagnostic test kit which is able to detect 16 different EML4-ALK fusion genes of tissue from non-small cell lung cancer (NSCLC) patients using peptide nucleic acid (PNA) probes in a real-time PCR system. The PANAMutyper™ EML4-ALK Screening Kit is intended as an aid for screening EML4-ALK fusion-positive NSCLC patients who would be sensitive for receiving ALK inhibitor therapy such as crizotinib.